Neil Exter has been steering Pliant Therapeutics since 2015, bringing over 30 years of experience in business development and strategy in the biotech and tech sectors. He holds an MBA from Harvard, along with degrees from Stanford and Cornell. His...

Neil Exter has been steering Pliant Therapeutics since 2015, bringing over 30 years of experience in business development and strategy in the biotech and tech sectors. He holds an MBA from Harvard, along with degrees from Stanford and Cornell. His past roles include Chief Business Officer at Alantos Pharmaceuticals, where he led a successful sale to Amgen, and Vice President of Business Development at Millennium Pharmaceuticals. In 2022, he retired from the board but left a significant mark on the company, showcasing his commitment to fostering growth and innovation. Exter's compensation reflects his contribution, hitting around $10.9 million in 2022, largely attributed to stock options and performance bonuses. During his tenure, he showed a knack for aligning business goals with the broader interests of stakeholders. Notably, the share value of Pliant Therapeutics experienced fluctuations during his leadership, reportedly boosting his personal investments significantly, with insider trading transactions valued in the millions throughout 2021 and 2022. His track record illustrates a strong link between strategic leadership and company performance.